anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Transgenic T cells and vectors for making transgenic T cells are described. The vectors can include a nucleic acid encoding a membrane-bound anti-IL6 (mb-alL6) single chain variable fragment (scFv), and the transgenic T cells can express mb-alL6. The transgenic T cells are useful for suppressing proliferation of IL-6-dependent cells, reducing IL-6 concentration, or both. In one embodiment, the vector is a bicistronic construct encoding the mb-alL6 and an anti-CD19-41 BB-003ζ chimeric antigen receptor (CAR). In another embodiment, an anti-IL-6 scFv can be linked to a 41 BB and 003ζ domains to form an anti-IL-6 CAR. The transgenic T cells expressing said constructs can reduce the linker risk of cytokine release syndrome (CRS) in cancer patients being treated with CAR T cell or for the treatment of autoimmune diseases and inflammatory diseases in which cytokines are involved in pathogenesis.
Frontotemporal dementia (FTD) is a devastating disorder and one the most common neurodegenerative diseases in middle age. The most prominent early manifestations of bvFTD ("behavior variant" FTD) are not the memory and other cognitive deficits typical of Alzheimer's disease (AD) but, rather, disturbance in social or interpersonal behavior. A basic manifestation of this disorder is a disturbance in the emotions and motives that drive social and moral behavior. In fact, bvFTD is an incredible window to the neuroscience of social behavior. This study will help clarify the neurobiological substrates of sociomoral emotions and their associated clinical features. The findings of this proposal can have major implications for understanding the interaction between brain and social behavior and for designing future research on the basic mechanisms of social neuroscience. This research aims to document the loss of sociomoral emotions (SME) compared to primary emotions in patients with bvFTD vs. patients with AD and normal controls. We need to show that these findings are specific to bvFTD and not present in Alzheimer's disease or normal controls. The project consists of three integrated parts: 1) behavioral measures that include observations in naturalistic settings, behavioral experiments, and behavioral scales; 2) psychophysiological reactivity (i.e., measures of heart rate, blood pressure changes, galvanic skin response, facial electromyography, and facial temperature) to social and emotional stimuli; and 3) brain localization of changes in sociomoral emotions with magnetic resonance imaging technology.
BACKGROUND: Dyspepsia is a prevalent condition in the general population. Besides organic causes, the differential diagnosis of dyspepsia includes functional dyspepsia (FD) and gastroparesis (GP) which share similar pathophysiological mechanisms and clinical presentation. So far, no study investigated the prevalence of FD and GP in a primary care in Belgium.
METHODS: Data were obtained from Intego, a Flemish-Belgian general practice-based morbidity registration network. From 586,164 patients between 2000 and 2021, we selected patients with ICD-10 code for FD and GP. Patients with organic gastrointestinal diseases were excluded. We determined demographics and comorbidities of FD/GP. For prevalence and incidence calculation, we included those who consulted their general practitioners at least once in the given year. Pair-wise comparison was conducted to access the impact of comorbidities on risk of FD/GP.
KEY RESULTS: Between 2011 and 2021, the prevalence of FD/GP ranged from 1.03% to 1.21%. The incidence of FD/GP ranged from 109 to 142 per 100,000 adults. In total 5242 cases of FD/GP were identified. These cases shared commonly coexisting diagnoses of gastroesophageal reflux disease (18.8%), irritable bowel syndrome (17.1%), and chronic constipation (18.7%). Patients with somatization/anxiety/depression had significantly higher risk of FD/GP, compared to the control (OR 1.38, 95% CI 1.19-1.61, p < 0.01).
CONCLUSIONS AND INFERENCES: The prevalence (1.03%-1.21%) and incidence (109-142/100,000) of FD/GP in primary care over last decade appear to conflict with epidemiological research in the general population. The discrepancies suggest a potential lack of awareness of FD and GP among physicians and/or patients in Flemish-Belgium.
According to the present invention, disclosed are a rice embryo bud sheet mask pack for skin and a manufacturing method thereof. The rice embryo bud sheet mask pack for skin comprises a mask sheet layer and a protection film. The mask sheet layer includes rice embryo bud powder. According to the present invention, the mask pack sheet is manufactured by rice embryo buds to have rich nutrients and enough moisture without any solutions, thereby retaining the supply of proper moisture during attachment. In addition, the present invention maintains cooling over three hours to transfer active ingredients continuously. Unlike existing method for putting a sheet inside a pouch and injecting a skin improving solution, the present invention uses only solutions contained in the sheet to change sizes by rolling or folding the rice embryo bud sheet. In addition, the present invention can add various active ingredients to the rice embryo sheet as necessary, and implement various colors, and be used as inflammation alleviating medicine, a burn treatment and an agent for improving atopy according to additives with an excellent skin attaching capacity.
Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
1. A process of manufacturing of formulation of topical beta-blockers with improved efficacy comprising the following steps: i) a. Making aqueous solution of Beta-blocker with or without physiologically acceptable excipients, buffers and preservatives with defining pH and adjusting it if needed. b. Making a gel of known gel forming substance with or without physiologically excipients buffers and preservatives in a separate vessel, with defining pH and adjusting it if needed. ii) Adding aqueous solution of Beta-blockers at step i (a) into a prepared gel of step i (b) while stirring slowly. iii) Adjusting the pH and volume before finally autoclaving and packaging. 2. A process as claimed in claim 1, wherein Beta-blockers can be selected from topical Beta-blockers used to reduce intraocular pressure, e. g. Timolol, Betaxolol, Carteolol, Metipranalol. 3. A process as in claim 1 to 2, wherein concentration of carbopol can be from 0.5% to 5%. 4. A process as claimed in claim 1 to 3, in which physiologically acceptable buffers, excipients and preservatives are used. 5. A process as claimed in claim 1 to 4, wherein pH of formulation is finally adjusted to 6.0 to 8.0 preferably between 6.5 and 7.5. 6. A process as claimed in claim 1 to 5, wherein formulation is autoclaved before packaging.
A kind of quinazoline (quinazoline) Alkaloid compound and preparation method thereof and the application as growth of tumour cell inhibitor, during preparation first in bacterium culture medium to gorgonian endogenetic fungus Scopulariopsis? sp. (TA01-33) carries out spawn culture, in the fermentation medium fermentation culture is carried out to this fungi again, then by gained filtering fermentation liquor, removing thalline, by filtrate reduced in volume, be extracted with ethyl acetate; Normal phase silicagel column chromatography, Sephadex is carried out after extraction liquid is concentrated? LH-20 gel filtration chromatography, concentrates gained elutriant, obtains colourless crystallization, fumiquinazoline? L.The quinazolin allkaloids compound fumiquinazoline that the present invention obtains from thalassiomycetes? L has selective inhibitory activity to lung cell A549, can be used for exploitation growth of tumour cell inhibitor, and raw material can carry out scale operation, not by resource limit, therefore have a extensive future.
Use of a product (I), comprising an isolated protein N comprising a 422 amino acid (SEQ ID No. 37) sequence fully defined in the specification; a polypeptide corresponding to N or C-terminal linkage of the protein with a label; an antibody or a fragment of monoclonal/polyclonal antibody directed against protein N; and a chip/filter of the protein/polypeptide to prepare agents to detect infection by corona virus associated with SARS, is new. Use of a product (I), comprising: (a) an isolated protein N (i) comprising a fully defined 422 amino acid (SEQ ID No. 37) sequence given in the specification; (b) a polypeptide (ii) corresponding to an N-terminal or C-terminal linkage of the protein N (SEQ ID No. 37) with a label; (c) an antibody (iii) or a fragment (iv) of monoclonal or polyclonal antibody directed against the protein N; and (d) a chip or a filter of the protein or polypeptide comprising (i-iv), for the preparation of agents to detect an infection by a corona virus associated with severe acute respiratory syndrome (SARS) and optionally of serotype of a corona virus associated with SARS. Independent claims are also included for: (1) detection of an infection by a corona virus associated with SARS from a biological sample comprising: contacting the biological sample with (i-iv) or a chip or a filter with (i) or (ii), and the revelation of the antigen-antibody complex by all appropriate means; (2) a kit for detection of an infection by a corona virus associated with SARS, comprising at least one of the reactive product (I); (3) immunogen composition (II) comprising at least one product (a protein (i) or a polypeptide (ii) and nucleic acid molecules coding the proteins and the polypeptides); (4) immune complex formed by an antibody directed specifically against an epitope of corona virus associated with SARS, and an isolated or purified protein of SEQ ID No. 37 or a polypeptide corresponding to the N-terminal or C-terminal linkage of the protein N with a label; and (5) use of an isolated or purified polynucleotide comprising one of 2 fully defined 1377 base pair sequences (SEQ ID No. 36 and 38) given in the specification and by a polynucleotide coding for a polypeptide corresponding to the N-terminal or C-terminal linkage of the protein N (SEQ ID No. 37) with a label, to induce the production of an antibody directed against the coded protein by the polynucleotide and capable of recognizing specifically an epitope of corona virus associated with SARS. ACTIVITY : Respiratory-Gen; Virucide. No biological data given. MECHANISM OF ACTION : Vaccine.
This Nordic Myeloma Study Group study is a phase 2 study for advanced multiple myeloma (MM) patients below 75 years of age. The main aim of this study is to assess the overall response rate (ORR) with a new drug combination, carfilzomib + elotuzumab + dexamethasone (CAR-ELO-Dex). Even if this is not a randomized study rough comparisons can be done with earlier reports of different regimens in the same clinical situation. In addition, safety assessment is of critical importance for a new regimen. A modern concept is to study the depth of complete responses (CR) with a sensitive multiparameter flow cytometry (MFC) method for minimal residual disease (MRD) assessment - an endpoint that is mostly lacking in previous studies for this patient population. We assume that treatment with this new combination of CAR + ELO + Dex will produce at least as good responses as the most efficient regimens so far used in this clinical situation, and there will be a substantial proportion of CR responses with MRD-negativity which can be regarded as an indicator of high-level treatment efficacy and which gives a good basis for comparisons of treatment efficacy between different study regimens in future.

The target population of the study is the patients who have relapsed or progressed after 1 to 3 prior treatment lines in which PI (bortezomib and/or ixazomib) and/or lenalidomide have been included. The primary endpoint is overall response rate while the secondary endpoints include complete remission, duration of response, assessment of the depth (quality) of CR with MRD measurement by flow cytometry, estimation of progression free survival (PFS) and time to next treatment, and evaluation of adverse events and safety.
Participants will receive a multi-layered, social marketing campaign which is deemed culturally appropriate. This will occur over a 6 month -time period. Rates will be observed at 0, 6, and 12 months.
The Cingal 13-02 study is a follow-on study to the recently completed clinical trial Cingal 13-01 \[NCT01891396\]. Cingal 13-01 was a multi-center, randomized, double-blind, Phase III study that enrolled 368 subjects at up to 20 sites in Canada and Europe. The Cingal 13-01 study objective was to assess the safety and effectiveness of a single injection of Cingal® for relief of joint pain and symptoms in patients with osteoarthritis (OA) of the knee. The study had three arms: the Cingal® investigational arm, an active comparator arm (Monovisc®) and a control arm (saline). Cingal 13-02 is designed to evaluate the safety of an open-label injection of Cingal® in subjects who received a study injection in the Cingal 13-01 trial. Sites that enrolled 5 or more subjects in the Cingal 13-01 study were eligible to participate in the Cingal 13-02 study. All subjects at these sites who met enrollment criteria had the option to participate in the follow-on study.
The present invention relates to the technical field of organism and medicine engineering. The world approximately has 1.7 hundred millions of HCV infected people, and more than 70% of HCV infection can be developed to chronic infection. The combination of E2 mediated HCV of HCV envelope protein and target cells relates to the most key protein of HCV infection, but E2 protein belongs to low expression protein. The protein expressed by mammalian cells obtained by a gene recombination method is quite difficult. The present invention aims to provide a method repressing hepatitis C virus envelope protein E2 by the high efficiency secretion of mammalian cells. The method constitutes novelmammalian cell expression plasmid which can express target gene E2 protein in high level, and express sieving marking glutamine synthetase in low level. The present invention can prepare recombination HCV coating E2 protein of HCV envelope protein natural biological function and antigenicity in a batch mode, establish foundation for a serologically detection reagent infected by HCV and HCV vaccine, and provide important material for the research of HCV molecular virology.
Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 \[23\], CBO 2008 \[24\]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
Patients in this group receive usual monitoring and treatment regimen is left to the discretion of the treating physicians. At inclusion, patients receive a phone call to collect data.at 1 month a Face to Face visit is planned at the pneumology clinic which also unifies the criteria for monitoring and treatment of respiratory disease. Whenever patients came to the emergency room (ER), they were evaluated by the Pneumologist in charge, ergo maintaining a similar approach in the assessment of ERs and deciding whether the patient should be admitted or discharged, independently of their group assignment.
The present invention relates to a special medicine for treating gastropathy, which belongs to an oral medicine for treating gastropathy. The present invention comprises components of 60 wt% to 75 wt% of furazolidone tablets and 40 wt% to 25 wt% of benzylbenzimidazole hydrochloride tablets, wherein the components are mixed and ground, and the ground components are processed through sieving through a sieve of 400 meshes, bottling for being sealed for 3 to 7 days and encapsulation according to 0.1 to 0.2g per capsule. The medicine is taken for two capsules every day, one is taken after breakfast, and the other is taken after supper. A month is a big course of treatment, and discontinuity is not allowed during the course of treatment. The present invention has a radical cure effect on treating perennial senile gastropathy, gastritis, chronic gastritis, superficial gastritis, gastric ulcer and gastroptosis. Compared with the existing medicine, the present invention has a good effect on treating enteritis, colitis and duodenal ulcer. A total effective rate reaches up to 95%, and a radical cure rate can reach up to more than 80%.
Individuals who are found to be eligible to participate will have two study interventions: An 8-week meal replacement therapy period in which they are asked to reduce their BMI by \>5%. Participants will be asked to strictly follow the individually-prescribed eating regimen which will include meal replacement shakes and/or frozen meals to be used for breakfast and lunch. For dinner, the study will provide pre-packaged frozen entrée meals to be consumed with two servings of fruit and three servings of vegetables per day. Meal replacement compliance will be assessed by requiring participants to maintain a dietary log throughout the study. The percentage of days for which the protocol was followed (no additional calories consumed) will serve as the primary metric of compliance.

Participants will also receive a standardized lifestyle/behavioral modification counseling every 2 weeks throughout the entire study, which will be delivered at each in-person study visit and via virtual platform of phone when there is no in-person study visit scheduled. The lifestyle curriculum will incorporate evidence-based behavior change principles including dietary modification, energy expenditure modification, behavior modification and family involvement and support. To ensure fidelity and adherence to the delivery protocol, a manual will be developed for each session that trained staff will follow when administering the curriculum.
PURPOSE:To obtain the subject composition capable of stably releasing a moderate aroma for a long period by converting a perfume compound into any derivative of a glycoside, a phosphoric acid ester, an amino acid and a carboxylic acid derivatives and blending the resultant perfume therein. CONSTITUTION:This sustained release aromatic composition for the human body is obtained by blending a specific derivative of a perfume therein and capable of stably releasing an aroma essential to the perfume for a long period. One or more of a glycoside, a phosphoric acid, an amino acid and a carboxylic acid derivatives are cited as the derivative of the perfume. The derivative is blended in the composition to decompose the derivative by dermal indigenous bacteria and slowly and stably emit the aroma for a long period. The perfume compound is especially preferably converted into the glycoside having beta-bonds and then blended in the sustained release aromatic composition for an antiperspirant. Bacterium of the genus Corynebacterium concerned in osmidrosis axillae are capable of stably emitting an aroma from the perfume glycoside having the beta-bonds. The composition can be used for enhancing the aroma and further the modification of the aroma.
A rejuvenating hair oil system with a pre-shampoo treatment and a post-shampoo treatment and a method of use that promotes healthful hair growth and improved hair appearance. The pre-shampoo treatment is a mixture of oils that provides moisturization as well as healing the scalp. The post-shampoo treatment is a mixture that contains a variety of oils and extracts derived from fruit, herbs, plants, animals as well as the flowers and seeds of various trees. The natural oil carriers are generally also act as moisturizers. Other oils and extracts provide antioxidants, anti-inflammatory compounds, antimicrobials, and penetrating compounds. The pre-shampoo treatment is applied to the hair and scalp five to ten minutes before shampooing and the hair is covered with a plastic cap. In between shampooing, a small amount of the post-shampoo treatment is applied to the hair and scalp as needed.
The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
BACKGROUND: Childhood obesity and hypertension are growing concerns globally, especially in developing countries. This study investigated the association between overall and central obesity at baseline, and prehypertension or hypertension at follow-up among preadolescent school children in urban Karachi, Pakistan.
METHODS: This is a sub study with cohort design embedded within a feasibility trial on School Health Education Program in Pakistan (SHEPP) in preadolescents aged 6-11 years, attending two private schools conducted from 2017 to 2019. Hypertension or prehypertension at follow-up were the outcomes and obesity or central obesity at baseline were the exposure variables. Hypertension was defined as systolic blood pressure and/or diastolic blood pressure ≥ 95th percentile for age, sex, and height. Obesity was defined as body mass index for-age and sex ≥ 95th percentile, whereas central obesity was determined by waist circumference measurements ≥ 85th percentile of age, sex, and height specific cut-offs. Logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to identify risk factors for hypertension and prehypertension.
RESULTS: Analysis was conducted for 908 participants, evenly distributed with 454 boys and 454 girls. Hypertension was observed in 19.8% of the preadolescents, with rates of 18.5% in boys and 21.0% in girls. Prehypertension was found in 16.8% of preadolescents, with 18% among boys and 16% among girls. Additionally, 12.8% of preadolescents were classified as obese and 29.8% had central obesity. Obesity at baseline was associated with hypertension at followup (OR 8.7, 95% CI 3.5, 20.4) in the final model after adjusting for age, gender, physical activity, sedentary behavior, fruits, vegetable intake and hypertension at baseline. Central obesity at baseline also yielded high odds, with prehypertension (OR 1.9, 95% CI 1.4, 2.8) and hypertension (OR 2.7, 95% CI 1.9, 3.9) at follow up in the final model.
CONCLUSION: This study highlights a concerning prevalence of hypertension and prehypertension among preadolescent school-going children. Obesity and central obesity at baseline emerged as significant predictive factors for hypertension or prehypertension at followup within this cohort. The findings emphasize the urgency of implementing comprehensive school health education programs aimed at early detection and effective management of hypertension during childhood and adolescence in school settings.